Nathalie Clement

Associate Program Director & Associate Professor • Powell Gene Therapy Center

Dr. Clément has 25+ years of experience in the field of Gene Therapy, with industry leading expertise in viral vectors, specifically adeno-associated virus (AAV). Previously, as the Associate Director of the Powell Gene Therapy Center, UFL, she led AAV production and process development at research, preclinical and clinical grades. Dr. Clément oversaw manufacturing, release and stability campaigns of more than eight AAV INDs, including CMC preparation. Her lab’s research focused on developing scale up platforms using HSV or transfection systems in suspension. Dr. Clément then joined Resilience as the head of the Process Development group for Viral Vaccines and Gene Therapy, where she oversaw production at scale up to 200L in suspension format, and in large scale adherent platforms. Recently, Dr. Clément has joined a new stealth gene therapy startup as VP to lead the AAV vector development efforts.

Also Speaking

Susan Nichols

President and Chief Executive Officer • Propel Biosciences

Haro Hartounian

Senior Vice President and General Manager • BioCentriq

Gerry Farrell

Chief Operating Officer • Fujifilm Diosynth Biotechnologies

Event Info


Fun Run